14 results on '"Argento, C."'
Search Results
2. Movement abnormalities in the left ventricle of Thalassemia Major patients
- Author
-
TUDISCA, Chiara, GRASSEDONIO, Emanuele, MIDIRI, Massimo, Meloni, A, Argento, C, Restaino, G, Giannotti, G, Lombardi, M, Pepe, A., Tudisca, C, Meloni, A, Grassedonio, E, Argento, C, Restaino, G, Giannotti, G, Lombardi, M, Midiri, M, and Pepe, A
- Subjects
genetic structures ,MR ,Cardiac, MR, Diagnostic procedure ,Diagnostic procedure ,Cardiac - Abstract
Aims and objectives Methods and materials Results Conclusion Personal information References, Aims and objectives: Movement abnormalities of the left ventricle (LV) have been reported in thalassemia major (TM) patients [1]. Movement abnormalities can be detected through a qualitative analysis of cine cardiovascular magnetic resonance (CMR) images. Moreover, CMR...
- Published
- 2014
- Full Text
- View/download PDF
3. Normal serum concentrations of anti-Müllerian hormone in women with regular menstrual cycles
- Author
-
Marca, A. L., Sighinolfi, G., Giulini, S., Traglia, M., Argento, C., Sala, C., Masciullo, C., Volpe, Annibale, Toniolo, D., and LA MARCA, Antonio
- Subjects
Adult ,Anti-Mullerian Hormone ,Oral ,Aging ,endocrine system ,medicine.medical_specialty ,Adolescent ,endocrine system diseases ,Cross-sectional study ,media_common.quotation_subject ,European Continental Ancestry Group ,Reproductive Endocrinology ,Normal serum ,White People ,Reference Values ,Internal medicine ,medicine ,Humans ,Ovarian reserve ,Contraceptives ,Cross-Sectional Studies ,Female ,Menstrual Cycle ,Middle Aged ,Menstrual cycle ,media_common ,biology ,urogenital system ,business.industry ,Obstetrics and Gynecology ,Anti-Müllerian hormone ,female genital diseases and pregnancy complications ,Endocrinology ,Reproductive Medicine ,Ageing ,biology.protein ,business ,hormones, hormone substitutes, and hormone antagonists ,Contraceptives, Oral ,Developmental Biology ,Hormone - Abstract
Anti-Müllerian hormone (AMH) has become the 'molecule of the moment' in the field of reproductive endocrinology. Indeed, it is valuable as a means of increasing understanding of ovarian pathophysiology and for guiding clinical management across a broad range of conditions. However, no normative values have been established for circulating AMH in healthy women. In this cross-sectional study, 277 healthy females (aged 18-50 years) were included. AMH was measured by commercial enzyme-linked immunosorbent assay. Serum AMH concentrations show a progressive decline with female ageing. The age-related changes in AMH were best fitted by a polynomial function. Mean AMH concentrations were not modified by past use of oral contraceptive and were independent of parity of women. Age-specific normative values for circulating AMH concentration were established. AMH concentrations seem to be independent of the reproductive history of the patient.
- Published
- 2010
4. Isatis canescens is a rich source of glucobrassicin and other health-promoting compounds
- Author
-
Stefania Galletti a, Manuela Bagatta a, Ferdinando Branca b, Sergio Argento c, Gina Rosalinda De Nicola a, Stefano Cianchetta a, Renato Iori a, Paolino Ninfali d, Galletti, Stefania, Bagatta, Manuela, Branca, Ferdinando, Argento, Sergio, De Nicola, Gina Rosalinda, Cianchetta, Stefano, Iori, Renato, and Ninfali, Paolino
- Subjects
glucosinolate ,ORAC ,chemoprevention ,Indoles ,Glucosinolates ,Flowers ,Health Promotion ,Isati ,Chemoprevention ,Antioxidants ,Phenols ,phenol ,Anticarcinogenic Agents ,flavonoid ,Anticarcinogenic Agent ,glucobrassicin ,Isatis ,Flavonoids ,Nutrition and Dietetics ,Phenol ,food and beverages ,Glucosinolate ,Glucobrassicin ,Italy ,Flower ,Indole ,Flavonoid ,Antioxidant ,Agronomy and Crop Science ,Biotechnology ,Food Science - Abstract
BACKGROUND: Glucobrassicin (GBS), a glucosinolate contained in many brassica vegetables, is the precursor of chemopreventive compounds such as indole-3-carbinol. Large amounts of GBS would be needed to perform studies aimed at elucidating its role in the diet. This studywasmainly undertaken to evaluate the flower buds of Isatis canescens as a source forGBS purification. In order to investigate the health-promoting potential of this species, glucosinolate, phenol and flavonoid content aswell as the whole antioxidant capacity were also determined. Flower bud samples were collected in four localities around Mount Etna in Sicily, Italy, where I. canescens is widespread, as they are locally traditionally eaten. RESULTS: I. canescens flower buds displayed high GBS concentrations, up to 60 mol g-1 dry weight. The purification method consisted of two chromatographic steps,which made it possible to obtain GBSwith a purity of 92-95%,with a yield of 21 g kg-1. The total glucosinolates, phenols, flavonoids and antioxidant activitywere considerable,with the southern locality showing the highest concentrations for all the phytochemicals. CONCLUSION: I. canescens flower buds represent a naturally rich source of GBS, at a level suitable for its purification. Furthermore, flower bud consumption could provide an intake of health-promoting compounds, with possible antioxidant and chemopreventive properties. © 2014 Society of Chemical Industry
- Published
- 2015
5. Normal serum levels of anti-Mullerian hormone in women with regular menstrual cycles
- Author
-
La Marca, A, Sighinolfi, G, Traglia, Michela, Argento, C, Sala, C, Masciullo, C, Volpe, A, Toniolo, D., La Marca, A, Sighinolfi, G, Traglia, Michela, Argento, C, Sala, C, Masciullo, C, Volpe, A, and Toniolo, D.
- Subjects
reproductive endocrinology ,amh - Abstract
Anti-Mu ̈llerian hormone (AMH) has become the ‘molecule of the moment’ in the field of reproductive endocrinology. Indeed, it is valuable as a means of increasing understanding of ovarian pathophysiology and for guiding clinical management across a broad range of conditions. However, no normative values have been established for circulating AMH in healthy women. In this cross-sectional study, 277 healthy females (aged 18–50 years) were included. AMH was measured by commercial enzyme-linked immunosorbent assay. Serum AMH concentrations show a progressive decline with female ageing. The age-related changes in AMH were best fitted by a polynomial function. Mean AMH concentrations were not modified by past use of oral contraceptive and were independent of parity of women. Age-specific normative values for circulating AMH concentration were established. AMH concentrations seem to be independent of the reproductive history of the patient
- Published
- 2010
6. Complex networks: analysis and control
- Author
-
Argento, C
- Subjects
Settore ING-INF/04 - Automatica ,complex networks ,delay compensation ,identification ,method of stages ,curve fitting ,networked control systems ,tracking control - Published
- 2008
7. Deferiprone Versus Sequential Deferiprone-Deferoxamine Treatment in Thalassemia Major: A Five Years Multicenter Randomized Clinical Trial
- Author
-
Maggio, A, Capra, M, Cuccia, L, Gagliardotto, F, Magnano, C, Caruso, V, Gerardi, C, M G, Friscia, Argento, C, Campisi, S, Cantella, F, Cianciulli, P, Commendatore, F, D G, D’Ascola, Fidone, C, Filosa, A, Fragasso, A, Galati, M, Giuffrida, G, Giugno, R, Lombardo, T, Malizia, R, Meo, A, Rizzo, M, Roccamo, G, M A, Romeo, Violi, P, Pepe, A, D’Amico, G, and Morabito, A
- Published
- 2007
8. Effect of HCG treatment on ERK-2 expression and activity in human pregnant myometrial cells
- Author
-
Ticconi, C., Belmonte, A., Zicari, Alessandra, Araco, P., Argento, C., and Piccione, E.
- Published
- 2006
9. Double stimulation in the same ovarian cycle (DuoStim) is an intriguing strategy to improve oocyte yield and the number of competent embryos in a short timeframe
- Author
-
Roberta Venturella, Carlo Alviggi, Panagiotis Drakopoulos, Elisabetta Trabucco, Filippo Maria Ubaldi, Alberto Vaiarelli, Nicolò Ubaldi, Cindy Argento, Alessandro Conforti, Laura Rienzi, Danilo Cimadomo, Vaiarelli, A., Cimadomo, D., Argento, C., Ubaldi, N., Trabucco, E., Drakopoulos, P., Venturella, R., Conforti, A., Ggi, C. A., Rienzi, L., Ubaldi, F. M., Surgical clinical sciences, Centre for Reproductive Medicine - Gynaecology, and Faculty of Medicine and Pharmacy
- Subjects
Oocyte ,Genetic testing ,Stimulation ,Fertilization in Vitro ,Luteal phase ,Embryo Culture Techniques ,Andrology ,03 medical and health sciences ,0302 clinical medicine ,Ovulation Induction ,Pregnancy ,Obstetrics and Gynaecology ,Follicular phase ,medicine ,Humans ,Advanced maternal age ,Blastocyst ,030219 obstetrics & reproductive medicine ,business.industry ,Obstetrics and Gynecology ,Embryo ,medicine.disease ,Aneuploidy ,Embryo Culture Technique ,Time-to-Pregnancy ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Oocytes ,Female ,business ,Menstrual cycle ,Human - Abstract
Proper ovarian stimulation regimens are crucial for any patient undergoing in-vitro fertilization (IVF). However, maximizing the oocyte yield in advanced maternal age patients with poor or suboptimal response is still a challenge. In fact, no standard treatment has been outlined yet to manage these women. Across the last years, an improved efficiency of the IVF units via blastocyst culture, vitrification and reliable embryo selection approaches paved the way to the investigation of novel unconventional stimulation protocols, like double stimulation in a single ovarian cycle (DuoStim). DuoStim, by conjugating follicular phase stimulation (FPS) and luteal phase stimulation (LPS) in the same ovarian cycle, allows to maximize the number of oocytes obtained in a short timeframe, a precious outcome when we aim at shortening time to pregnancy. In this regard, LPS seems to contribute to conventional stimulation with more oocytes with a comparable competence as FPS, retrieved per ovarian cycle. Although any stimulation protocol which exploits anovulatory waves of follicular growth needs a thorough investigation, no evidence has been produced to question the safety of DuoStim, which to date represents the most intriguing strategy to treat poor prognosis in IVF.
- Published
- 2019
10. Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas
- Author
-
Giuseppe Lamberti, Alicia Tosoni, Dario de Biase, Alba A. Brandes, Alexandro Paccapelo, Antonella Mura, Chiara Maria Argento, Stefania Bartolini, Enrico Franceschi, Monica Di Battista, Michela Visani, Franceschi E., Mura A., Lamberti G., De Biase D., Tosoni A., Di Battista M., Argento C., Visani M., Paccapelo A., Bartolini S., and Brandes A.A.
- Subjects
0301 basic medicine ,Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Concordance ,medicine.medical_treatment ,Kaplan-Meier Estimate ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Glioma ,Internal medicine ,Medicine ,Humans ,RTOG ,DNA Modification Methylases ,neoplasms ,Risk criteria ,Aged ,low-grade glioma ,business.industry ,Tumor Suppressor Proteins ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,Isocitrate Dehydrogenase ,humanities ,Idh mutation ,Clinical trial ,Radiation therapy ,EORTC ,030104 developmental biology ,DNA Repair Enzymes ,030220 oncology & carcinogenesis ,Mutation ,Female ,Mgmt methylation ,Neoplasm Grading ,business - Abstract
Aim: European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria are used to choose treatment in low-grade gliomas. However, no data exist on their concordance. Methods: Low-grade glioma patients treated at our institution from 1998 to 2015 and assessable for both RTOG and EORTC criteria were included to analyze their concordance. Surgery extension, postsurgical treatments, molecular characteristics ( IDH mutation, MGMT methylation and 1p/19q codeletion) were recorded. Results: We included 99 patients. The concordance was low (50.5%; K = 0.127; p = 0.021) but for two subgroups: EORTC high-risk patients were also RTOG high-risk patients (concordance: 97.5%) and RTOG low-risk patients were also EORTC low-risk patients (concordance: 90.9%). Conclusion: The concordance between RTOG and EORTC criteria is low. Thus, clinical trials adopting different risk criteria are not comparable.
- Published
- 2019
11. Age-specific reference values for serum FSH and estradiol levels throughout the reproductive period
- Author
-
Antonio La Marca, Maddalena Plebani, Silvano Milani, Annibale Volpe, Cindy Argento, Valentina Grisendi, Renato Seracchioli, Elena Spada, Grisendi V, Spada E, Argento C, Plebani M, Milani S, Seracchioli R, Volpe A, and La Marca A.
- Subjects
Adult ,medicine.medical_specialty ,endocrine system ,Aging ,Serum fsh ,Adolescent ,Cross-sectional study ,Endocrinology, Diabetes and Metabolism ,Estradiol ,FSH ,nomogram ,reference values ,Biological Markers ,Cross-Sectional Studies ,Female ,Follicle Stimulating Hormone, Human ,Follicular Phase ,Humans ,Italy ,Linear Models ,Luminescent Measurements ,Ovary ,Pituitary Gland, Anterior ,Premenopause ,Reference Values ,Tertiary Care Centers ,Young Adult ,Up-Regulation ,Endocrinology ,Internal medicine ,Follicular phase ,medicine ,Young adult ,business.industry ,Obstetrics and Gynecology ,Nomogram ,medicine.disease ,medicine.anatomical_structure ,Reference values ,business ,Poor ovarian reserve ,hormones, hormone substitutes, and hormone antagonists ,Biomarkers - Abstract
High serum day 3 FSH levels are associated with poor ovarian reserve and reduced fertility, but the interpretation of FSH values according to age is still not univocal. The purpose of this study was to determine age-dependent reference values in women with regular menstrual cycles and FSH as a guide for specialists. The study was performed at the Department of Mother-Infant of a University-based tertiary care centre. One-hundred ninety-two healthy normal menstruating women were recruited for the study. All patients attended the department on menstrual cycle day 3 for a blood sample for FSH and estradiol determination. A linear relationship between FSH or estradiol serum levels and age was observed. The FSH level increased by 0.11 IU for every year of age (1 IU for every 9 years of age). The values of FSH and estradiol corresponding to the 5th, 25th, 50th, 75th, 95th centiles for any specific age have been calculated. Serum FSH levels need to be interpreted according to age-dependent reference values. Serum FSH levels on 95th centile for any age may represent a warning sign for reduced ovarian reserve.
- Published
- 2014
12. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients
- Author
-
Pietro Violi, R. Malizia, Domenico Giuseppe D'Ascola, Alessia Pepe, Alberto Morabito, Saveria Campisi, Gaetano Restivo Pantalone, Maria Antonietta Romeo, Calogera Gerardi, Michele Rizzo, Alessandra Quota, Christian Gluud, Aurelio Maggio, Paolo Cianciulli, Gennaro D'Amico, Francesco Gagliardotto, Aldo Filosa, Carmelo Magnano, Crocetta Argento, Paolo Rigano, Luciano Prossomariti, Vincenzo Caruso, Carmelo Fidone, Angela Vitrano, Liana Cuccia, Marcello Capra, Pantalone, GR, Maggio, A, Vitrano, A, Capra, M, Cuccia, L, Gagliardotto, F, Filosa, A, Romeo, MA, Magnano, C, Caruso, V, Argento, C, Gerardi, C, Campisi, S, Violi, P, Malizia, R, Cianciulli, P, Rizzo, M, D'Ascola, DG, Quota, A, Prossomariti, L, Fidone, C, Rigano, P, Pepe, A, D'Amico, G, Morabito, A, and Gluud, C
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Pyridones ,Thalassemia ,Clinical Biochemistry ,Deferoxamine ,Iron Chelating Agents ,Gastroenterology ,Drug Administration Schedule ,law.invention ,chemistry.chemical_compound ,Young Adult ,Randomized controlled trial ,law ,Internal medicine ,Medicine ,Humans ,Deferiprone ,Adverse effect ,Genetics (clinical) ,Survival analysis ,business.industry ,Biochemistry (medical) ,Serum ferritin level ,beta-Thalassemia ,Hematology ,Iron chelation therapy ,medicine.disease ,Chelation Therapy ,Treatment Outcome ,chemistry ,Drug Therapy, Combination ,Female ,business ,Thalassemia, Iron overload, Iron chelation therapy, Deferiprone (L1), Deferroxamine (DFO) ,medicine.drug ,Follow-Up Studies - Abstract
In β-thalassemia major (β-TM) patients, iron chelation therapy is mandatory to reduce iron overload secondary to transfusions. Recommended first line treatment is deferoxamine (DFO) from the age of 2 and second line treatment after the age of 6 is deferiprone (L1). A multicenter randomized open-label trial was designed to assess the effectiveness of long-term alternating sequential L1-DFO versus L1 alone iron chelation therapy in β-TM patients. Deferiprone 75 mg/kg 4 days/week and DFO 50 mg/kg/day for 3 days/week was compared with L1 alone 75 mg/kg 7 days/week during 5-year follow-up. A total of 213 thalassemia patients were randomized and underwent intention-to-treat analysis. Statistically, a decrease of serum ferritin levels was significantly higher in alternating sequential L1-DFO patients compared with L1 alone patients (p = 0.005). Kaplan-Meier survival analysis for the two chelation treatments did not show statistically significant differences (log-rank test, p = 0.3145). Adverse events and costs were comparable between the groups. Alternating sequential L1-DFO treatment decreased serum ferritin concentration during a 5-year treatment by comparison to L1 alone, without significant differences of survival, adverse events or costs. These findings were confirmed in a further 21-month follow-up. These data suggest that alternating sequential L1-DFO treatment may be useful for some β-TM patients who may not be able to receive other forms of chelation treatment.
- Published
- 2011
13. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassemia major patients: a randomised clinical trial
- Author
-
Paolo Rigano, Luciano Prossomariti, Domenico Giuseppe D'Ascola, Michele Rizzo, Christian Gluud, Aldo Filosa, Vincenzo Caruso, Calogera Gerardi, Carmelo Magnano, Pietro Violi, Saveria Campisi, Alessia Pepe, Gennaro D'Amico, Paolo Cianciulli, Carmelo Fidone, Alberto Morabito, Marcello Capra, Aurelio Maggio, Angela Vitrano, Francesco Gagliardotto, Alessandra Quota, Liana Cuccia, R. Malizia, Maria Antonietta Romeo, Crocetta Argento, Maggio, A, Vitrano, A, Capra, M, Cuccia, L, Gagliardotto, F, Filosa, A, Romeo, MA, Magnano, C, Caruso, V, Argento, C, Gerardi, C, Campisi, S, Violi, P, Malizia, R, Cianciulli, P, Rizzo, M, D’Ascola, DG, Quota, A, Prossomariti, L, Fidone, C, Rigano, P, Pepe, A, D’Amico, G, Morabito, A, and Gluud, C
- Subjects
Adult ,Male ,medicine.medical_specialty ,Randomization ,Adolescent ,Pyridones ,Administration, Oral ,Kaplan-Meier Estimate ,Deferoxamine ,Infusions, Subcutaneous ,Iron Chelating Agents ,Gastroenterology ,law.invention ,Young Adult ,chemistry.chemical_compound ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,Deferiprone ,Adverse effect ,Decreased serum ferritin ,Survival analysis ,business.industry ,Hematology ,Surgery ,Clinical trial ,Chelation, thalassaemia, clinical trials, red blood cell disorders, iron overload ,Treatment Outcome ,chemistry ,Ferritins ,Thalassemia ,Drug Therapy, Combination ,Female ,business ,Follow-Up Studies ,medicine.drug - Abstract
A multicentre randomized open-label trial was designed to assess the effectiveness of long-term sequential deferiprone–deferoxamine (DFO–DFP) versus DFP alone to treat thalassaemia major (TM). DFP at 75 mg/kg, divided into three oral daily doses, for 4 d/week and DFO by subcutaneous infusion (8–12 h) at 50 mg/kg per day for the remaining 3 d/week was compared with DFP alone at 75 mg/kg, administered 7 d/week during a 5-year follow-up. The main outcome measures were differences between multiple observations of serum ferritin concentrations. Secondary outcomes were survival analysis, adverse events, and costs. Consecutive thalassaemia patients (275) were assessed for eligibility; 213 of these were randomized and underwent intention-to-treat analysis. The decrease of serum ferritin levels during the treatment period was statistically significant higher in sequential DFP–DFO patients compared with DFP-alone patients (P = 0.005). Kaplan– Meier survival analysis for the two chelation treatments did not show any statistically significant differences (log-rank test, P = 0.3145). Adverse events and costs were comparable between the groups. The trial results show that sequential DFP–DFO treatment compared with DFP alone significantly decreased serum ferritin concentration during treatment for 5 years without significant differences regarding survival, adverse events, or costs.
- Published
- 2009
14. Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies
- Author
-
Michele Rizzo, Crocetta Argento, Angela Vitrano, Pietro Violi, R. Malizia, Domenico Giuseppe D'Ascola, Carmelo Magnano, Aurelio Maggio, Marcello Capra, Saveria Campisi, Francesco Cantella, Francesca Valeria Commendatore, Francesco Gagliardotto, Liana Cuccia, Giovanni Giugno, Rocca Cingari, Carmelo Fidone, Maria Antonietta Romeo, Paolo Rigano, Luciano Prossomariti, Anna Meo, Paolo Cianciulli, Gaetano Roccamo, Aldo Filosa, Maria Concetta Galati, Gaetano Giuffrida, Vincenzo Caruso, Turi Lombardo, Angela Ciancio, Calogera Gerardi, Maggio, A, Vitrano, A, Capra, M, Cuccia, L, Gagliardotto, F, Filosa, A, Magnano, C, Rizzo, M, Caruso, V, Gerardi, C, Argento, C, Campisi, S, Cantella, F, Commendadore, F, D’Ascola, DG, Fidone, C, Ciancio, A, Galati, MC, Giuffrida, G, Cingari, R, Giugno, G, Lombardo, T, Prossomariti, L, Malizia, R, Meo, A, Roccamo, G, Romeo, MA, Violi, P, Cianciulli, P, and Rigano, P
- Subjects
Male ,Thalassemia ,Kaplan-Meier Estimate ,law.invention ,chemistry.chemical_compound ,Randomized controlled trial ,law ,Cause of Death ,Neoplasms ,Deferiprone ,Prospective Studies ,Child ,Cause of death ,Hazard ratio ,Hematology ,Middle Aged ,Combined Modality Therapy ,Survival Rate ,Thalassemia, survival, chelation, treatment, trial, thalassemia major ,Combination ,Splenectomy ,Molecular Medicine ,Drug Therapy, Combination ,Female ,Adult ,medicine.medical_specialty ,Adolescent ,Pyridones ,Deferoxamine ,Iron Chelating Agents ,Young Adult ,Drug Therapy ,Internal medicine ,medicine ,Humans ,Blood Transfusion ,Chelation Therapy ,Heart Failure ,Kaplan-Meiers Estimate ,Proportional Hazards Models ,beta-Thalassemia ,Molecular Biology ,Survival rate ,Survival analysis ,business.industry ,Proportional hazards model ,Cell Biology ,medicine.disease ,Surgery ,chemistry ,business - Abstract
The prognosis for thalassemia major has dramatically improved in the last two decades. However, many transfusion-dependent patients continue to develop progressive accumulation of iron. This can lead to tissue damage and eventually death, particularly from cardiac disease. Previous studies that investigated iron chelation treatments, including retrospective and prospective non-randomised clinical trials, suggested that mortality, due mainly to cardiac damage, was reduced or completely absent in patients treated with deferiprone (DFP) alone or a combined deferiprone-deferoxamine (DFP-DFO) chelation treatment. However, no survival analysis has been reported for a long-term randomised control trial. Here, we performed a multicenter, long-term, randomised control trial that compared deferoxamine (DFO) versus DFP alone, sequential DFP-DFO, or combined DFP-DFO iron chelation treatments. The trial included 265 patients with thalassemia major, with 128 (48.3%) females and 137 (51.7%) males. No deaths occurred with the DFP-alone or the combined DFP-DFO treatments. One death occurred due to graft versus host disease (GVHD) in a patient that had undergone bone marrow transplantation; this patient was censored at the time of transplant. Only one death occurred with the DFP-DFO sequential treatment in a patient that had experienced an episode of heart failure one year earlier. Ten deaths occurred with the deferoxamine treatment. The main factors that correlated with an increase in the hazard ratio for death were: cirrhosis, arrhythmia, previous episode of heart failure, diabetes, hypogonadism, and hypothyroidism. In a Cox regression model, the interaction effect of sex and age was statistically significant (p-value
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.